Nucleus RadioPharma Raises Series A Extension Funding

Nucleus RadioPharma, a Rochester, MN-based integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, raised an undisclosed amount in a Series A extension funding.

Backers included AstraZeneca, GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri. Concurrent with the financing, Tyrell Rivers, PhD, Executive Director of Corporate Ventures at AstraZeneca, was named to the Board of Directors.

The company intends to use the funds to expand its development, supply, and commercial manufacturing capabilities to make targeted radiotherapies and theranostics more accessible to patients globally.

Led by CEO Charles S. Conroy, Nucleus RadioPharma is an innovative CDMO in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies. It provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Recognized for its flexible approach, the company offers multiple onboarding points to accommodate innovators at various stages of their product lifecycle.